Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer

Annals of Oncology

Volumn 16, Issue 2, 2005, Pages 247-252

  Schwartz, J ^a,b   Domchek, S M ^a   Hwang, W T ^a   Fox, K ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

Anemia; Breast cancer; Docetaxel; Dose dense; Doxorubicin; Erythropoietin; Hand foot syndrome; Neuropathy; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ANEMIA; BLOOD TRANSFUSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; LACRIMATION; MAJOR CLINICAL STUDY; NEUROPATHY; NEUTROPENIA; ONYCHOLYSIS; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SKIN TOXICITY;

EID: 14644406208     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi058     Document Type: Review

References (15)

1. Gianni AM, Piccart MJ. Optimizing chemotherapy dose density and dose intensity: new strategies to improve outcomes in adjuvant therapy for breast cancer. Eur J Cancer 2000; 36: S1-S3.
2. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-983.
3. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 1997; 24 (Suppl. 10): S3-S10.
4. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
5. Piccart MJ. Mathematics and oncology: a match for life? J Clin Oncol 2003; 21: 1425-1428.
6. DiLeo A, Crown J, Nogaret JM et al. A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer. Ann Oncol 2000; 11: 169-175.
7. Miller KD, McCaskill-Stevens W, Sisk J et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier oncology group. J Clin Oncol 1999; 17: 3033-3037.
8. von Minckwitz G, Costa SD, Raab G et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol 2001; 19: 3506-3515.
9. Jackisch C, von Minckwitz G, Eidtmann H et al. Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin cyclophosphamide/docetaxel in operable breast cancer: second interim analysis. Clin Breast Cancer 2002; 3: 276-280.
10. Zimmerman GC, Keeling JH, Burris HA et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995; 131: 202-206.
11. Holmes FA, Rowinsky EK. Pharmacokinetic profiles of doxorubicin in combination with taxanes. Semin Oncol 2001; 28: 8-14.
12. Eich D, Scharffetter-Kochanek K, Eich HT et al. Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer. Am J Clin Oncol 2002; 25: 599-602.
13. Vukelya S, Baker W, Burris HA 3rd, Keeling JH, Von Hoff D. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J Natl Cancer Inst 1993; 85: 1432-1433.
14. Scotte F, Tourani JM, Banu E et al. Assessment offrozen glove use in the prevention of decetaxel induced onycholysis and cutaneous reaction. Results of a multicenter case-control study. J Clin Oncol (ASCO Meeting Abstracts) 2004; 22: 14S, 8003.
15. Piccart MJ, Klijn J, Paridaens R. Corticosteroids significantly delay the onset of decetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997; 15: 3149-3155.